Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 4.72% is 26% below its 5-year average of 6.42%, near the low end of its 5-year range (3.68%–8.84%).
As of the fiscal period ended Tuesday, September 30, 2025. 28.48% below its 12-month average of 6.60%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
4.72%
RETURN ON EQUITY (ROE) AVG TTM
6.60%
RETURN ON EQUITY (ROE) AVG 3Y
6.50%
RETURN ON EQUITY (ROE) AVG 5Y
6.42%
RETURN ON EQUITY (ROE) AVG 10Y
6.98%
RETURN ON EQUITY (ROE) AVG 15Y
12.80%
RETURN ON EQUITY (ROE) AVG 20Y
14.93%
CURRENT VS TTM AVG
-28.48%
CURRENT VS 3Y AVG
-27.36%
CURRENT VS 5Y AVG
-26.46%
CURRENT VS 10Y AVG
-32.41%
CURRENT VS 15Y AVG
-63.12%
CURRENT VS 20Y AVG
-68.39%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-56.66%
vs the sector median at left
Becton, Dickinson and Company
Market Cap
$60.26B
Return on Equity (ROE)
4.72%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$62.18B
Return on Equity (ROE)
75.01%
TTM Avg
168.34%
3Y Avg
-32.99%
5Y Avg
148.52%
Market Cap
$54.46B
Return on Equity (ROE)
-56.13%
TTM Avg
-41.33%
3Y Avg
9.62%
5Y Avg
-22.30%
Market Cap
$68.46B
Return on Equity (ROE)
13.74%
TTM Avg
10.21%
3Y Avg
8.16%
5Y Avg
6.40%
Market Cap
$71.62B
Return on Equity (ROE)
14.08%
TTM Avg
14.72%
3Y Avg
15.95%
5Y Avg
23.11%
Market Cap
$48.18B
Return on Equity (ROE)
10.58%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
Market Cap
$46.67B
Return on Equity (ROE)
6.08%
TTM Avg
7.05%
3Y Avg
11.93%
5Y Avg
15.09%
Market Cap
$44.93B
Return on Equity (ROE)
70.38%
TTM Avg
60.82%
3Y Avg
72.53%
5Y Avg
81.69%
Market Cap
$79.64B
Return on Equity (ROE)
14.90%
TTM Avg
11.32%
3Y Avg
12.19%
5Y Avg
12.83%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Becton, Dickinson and Company (BDX) | $60.26B | 4.72% | 6.60% | 6.50% | 6.42% |
| Cencora, Inc. (COR)vs › | $62.18B | 75.01% | 168.34% | -32.99% | 148.52% |
| Cardinal Health, Inc. (CAH)vs › | $54.46B | -56.13% | -41.33% | 9.62% | -22.30% |
| Boston Scientific Corporation (BSX)vs › | $68.46B | 13.74% | 10.21% | 8.16% | 6.40% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $71.62B | 14.08% | 14.72% | 15.95% | 23.11% |
| Edwards Lifesciences Corporation (EW)vs › | $48.18B | 10.58% | 26.07% | 24.86% | 23.86% |
| Humana Inc. (HUM)vs › | $46.67B | 6.08% | 7.05% | 11.93% | 15.09% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $44.93B | 70.38% | 60.82% | 72.53% | 81.69% |
| Cigna Corporation (CI)vs › | $79.64B | 14.90% | 11.32% | 12.19% | 12.83% |
| IQVIA Holdings Inc. (IQV)vs › | $40.61B | 22.28% | 21.77% | 21.17% | 17.55% |
ROE
4.7%
ROA
2.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-09-30 | 6.61% |
| 2024-09-30 | 6.59% |
| 2023-09-30 | 5.75% |
| 2022-09-30 | 7.04% |
| 2021-09-30 | 8.84% |
| 2020-09-30 | 3.68% |
| 2019-09-30 | 5.85% |
| 2018-09-30 | 1.48% |
| 2017-09-30 | 8.50% |
| 2016-09-30 | 12.78% |
| 2015-09-30 | 9.70% |
| 2014-09-30 | 23.45% |
| 2013-09-30 | 25.64% |
| 2012-09-30 | 28.29% |
| 2011-09-30 | 26.32% |
| 2010-09-30 | 24.24% |
| 2009-09-30 | 23.95% |
| 2008-09-30 | 22.83% |
| 2007-09-30 | 20.40% |
| 2006-09-30 | 19.61% |
| 2005-09-30 | 21.99% |
| 2004-09-30 | 15.24% |
| 2003-09-30 | 18.88% |
| 2002-09-30 | 19.29% |
| 2001-09-30 | 17.25% |
| 2000-09-30 | 20.09% |
| 1999-09-30 | 15.59% |
| 1998-09-30 | 14.66% |
| 1997-09-30 | 21.66% |
| 1996-09-30 | 21.40% |
